BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19944256)

  • 1. The role of prophylaxis in the management of von Willebrand disease: today and tomorrow.
    Abshire T
    Thromb Res; 2009 Nov; 124 Suppl 1():S15-9. PubMed ID: 19944256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis in von Willebrand disease.
    Berntorp E
    Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
    Federici AB
    Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis in von Willebrand disease.
    Franchini M; Targher G; Lippi G
    Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
    Berntorp E
    Semin Thromb Hemost; 2006 Sep; 32(6):621-5. PubMed ID: 16977572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis and von Willebrand's disease (vWD).
    Abshire TC
    Thromb Res; 2006; 118 Suppl 1():S3-7. PubMed ID: 16580053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
    Shortt J; Dunkley S; Rickard K; Baker R; Street A
    Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term prophylaxis with intermediate-purity factor VIII concentrate (Haemate P) in a patient with type 3 von Willebrand disease and recurrent gastrointestinal bleeding.
    Coppola A; Cimino E; Conca P; De Simone C; Tufano A; Tarantino G; Cerbone AM; Minno G
    Haemophilia; 2006 Jan; 12(1):90-4. PubMed ID: 16409182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis in bleeding disorders.
    Oldenburg J
    Thromb Res; 2011 Jan; 127 Suppl 1():S14-7. PubMed ID: 21112077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The von Willebrand disease prophylaxis network (vWD PN): exploring a treatment concept.
    Berntorp E; Abshire T;
    Thromb Res; 2006; 118 Suppl 1():S19-22. PubMed ID: 16545435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevalence, pathophysiology, diagnosis and treatment of von Willebrand syndrome in orthopedic trauma patients].
    Kurth AA; Ludwig G; Scharrer I
    Orthopade; 1999 Apr; 28(4):366-74. PubMed ID: 10335531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.
    Holm E; Abshire TC; Bowen J; Álvarez MT; Bolton-Maggs P; Carcao M; Federici AB; Gill JC; Halimeh S; Kempton C; Key NS; Kouides P; Lail A; Landorph A; Leebeek F; Makris M; Mannucci P; Mauser-Bunschoten EP; Nugent D; Valentino LA; Winikoff R; Berntorp E
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):383-8. PubMed ID: 25688461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical diagnosis of von Willebrand disease.
    Federici AB
    Haemophilia; 2004 Oct; 10 Suppl 4():169-76. PubMed ID: 15479393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience of prophylactic treatment in von Willebrand disease.
    Lethagen S
    Thromb Res; 2006; 118 Suppl 1():S9-11. PubMed ID: 16616322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Willebrand's disease: clinical management.
    Federici AB; Castaman G; Thompson A; Berntorp E
    Haemophilia; 2006 Jul; 12 Suppl 3():152-8. PubMed ID: 16684011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. von Willebrand disease update: diagnostic and treatment dilemmas.
    Bolton-Maggs PH; Lillicrap D; Goudemand J; Berntorp E
    Haemophilia; 2008 Jul; 14 Suppl 3():56-61. PubMed ID: 18510523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.